Connor, Clark & Lunn Investment Management (CC&L)

Connor, Clark & Lunn Investment Management (CC&L)’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,700	Closed	-$25K	–	1250
2019 Q4	$25K	Buy	+15,700	New	+$14.9K	﹤0.01%	905
2017 Q1	–	Sell	-1,150	Closed	-$5K	–	1080
2016 Q4	$5K	Buy	1,150 +140	+14%	+$581	﹤0.01%	874
2016 Q3	$4K	Hold	1,010	–	–	﹤0.01%	826
2016 Q2	$3K	Hold	1,010	–	–	﹤0.01%	855
2016 Q1	$5K	Hold	1,010	–	–	﹤0.01%	818
2015 Q4	$12K	Buy	+1,010	New	+$13.5K	﹤0.01%	803

Other funds holding CTIC

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return